Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HRT advanced for three days, in of 122 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 24, 2023. You may want to consider a long position or call options on HRT as a result. In of 55 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HRT just turned positive on May 18, 2023. Looking at past instances where HRT's MACD turned positive, the stock continued to rise in of 24 cases over the following month. The odds of a continued upward trend are .
HRT moved above its 50-day moving average on June 02, 2023 date and that indicates a change from a downward trend to an upward trend.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 26 cases where HRT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HRT broke above its upper Bollinger Band on June 02, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HRT entered a downward trend on May 19, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.455) is normal, around the industry mean (7.906). P/E Ratio (6.766) is within average values for comparable stocks, (25.948). HRT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.998). HRT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.037). P/S Ratio (1.070) is also within normal values, averaging (1.534).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medical software
|MFs / NAME||Price $||Chg $||Chg %|
|Goldman Sachs Small/Mid Cap Value Instl|
|Matisse Discounted Cl-End Fd Strat Instl|
|Eventide Healthcare & Life Sciences I|
|Principal LargeCap Growth I R5|
|Fidelity Advisor® Strategic Real Ret I|
A.I.dvisor tells us that HRT and ADP have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that HRT and ADP's prices will move in lockstep.
|ADP - HRT|
|PAYX - HRT|
|NSP - HRT|
|UPWK - HRT|
|TBI - HRT|